http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105106132-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67729b8186b93122691ad7b178235bef |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate | 2015-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aa95577257e21a2e9c617263ec38668 |
| publicationDate | 2015-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105106132-A |
| titleOfInvention | Pharmic tadalafil composition granules for treating urological diseases |
| abstract | The invention discloses pharmic tadalafil composition granules for treating urological diseases, and belongs to the technical field of medicament. A composition is prepared from tadalafil, saccharose, glucose, glycine, polyethylene glycol and purified water. The tadalafil is a novel crystal-type compound, an X-ray powder diffraction pattern measured through a Cu-K alpha-ray is shown in graph 1, and the tadalafil is different from that reported in the prior art; according to experiments, it is found that the compound with the novel crystal-type structure has significantly improved water solubility and is low in impurity content and good in stability; the granules prepared from the novel crystal-type tadalafil compound is good in stability, low in impurity content and high in bioavailability, and the safety of clinical applications is improved. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106432281-A |
| priorityDate | 2015-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.